Paula Ghaneh
University of Liverpool
CancerInternal medicineRadiologySurgeryOncologyResectionPancreatitisChemotherapyPancreatic diseaseAdjuvantAdjuvant therapyPancreasFolinic acidPancreatic cancerGemcitabineIn patientCancer researchGeneral surgeryMedicineGastroenterology
288Publications
62H-index
11.2kCitations
Publications 283
Newest
#1Rebecca SaundersH-Index: 1
#2Faye HughesH-Index: 1
Last. Christopher HalloranH-Index: 25
view all 8 authors...
Objectives To assess both individual patient and institutional costs as well as outcomes in patients with pancreatic necrosis who underwent either endoscopic, minimal access or open pancreatic necrosectomy. These data can be used to evaluate clinical effectiveness with a view to informing local health care providers. Summary background data Intervention for infected pancreatic necrosis is associated with a high morbidity, mortality and long hospital stays. Minimal access surgical step-up approac...
Source
#3Richard WilkinH-Index: 5
#4H.W. CloustonH-Index: 2
Last. Kathryn WaiteH-Index: 5
view all 39 authors...
Source
#1Rebecca Saunders (University of Liverpool)
#1Rebecca SaundersH-Index: 1
Last. Christopher HalloranH-Index: 25
view all 5 authors...
Single Port Retroperitoneal Pancreatic Necrosectomy (SPRPN), a novel method to debride extra-pancreatic necrosis after failed conventional treatment, was undertaken in 7 patients with a median collection diameter of 98 x 85 x 124mm, with resolution at a median of 42 days and post-operative median stay of 47 days.
Source
#1Christopher M. Jones (University of Leeds)H-Index: 25
#2Ganesh RadhakrishnaH-Index: 11
Last. Somnath Mukherjee (University of Oxford)H-Index: 21
view all 18 authors...
Source
Source
#1Lucy OldfieldH-Index: 4
#2Rohith RaoH-Index: 1
Last. Eithne CostelloH-Index: 51
view all 13 authors...
Source
#1Robert C. Grant (Princess Margaret Cancer Centre)H-Index: 16
#2Kai Duan (UHN: University Health Network)
Last. Sandra Fischer (UHN: University Health Network)H-Index: 25
view all 20 authors...
Introduction No biomarker is clinically available to predict prognosis after surgical resection of pancreatic cancer beyond CA-19-9, a classical tumor marker. GATA6 is a transcription factor necessary for pancreaticogenesis that associates with the major transcriptomic subtypes of pancreatic cancer. In this study, we evaluated the prognostic utility of GATA6 expression in randomised adjuvant chemotherapy trials. Materials and Methods We retrospectively analyzed resection specimens in tissue micr...
Source
#1Paula GhanehH-Index: 62
#2Daniel H. PalmerH-Index: 44
Last. John P. NeoptolemosH-Index: 125
view all 20 authors...
2 CitationsSource
#1Lucy OldfieldH-Index: 4
Last. Eithne CostelloH-Index: 51
view all 12 authors...
Source
#2Lucy OldfieldH-Index: 4
Last. Eithne CostelloH-Index: 51
view all 10 authors...
Source